Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management
-
- Edward K Avila
- Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York , USA
-
- Steven Tobochnik
- Department of Neurology, Brigham and Women’s Hospital , Boston, Massachusetts , USA
-
- Sara K Inati
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, Maryland , USA
-
- Johan A F Koekkoek
- Department of Neurology, Leiden University Medical Center , Leiden , The Netherlands
-
- Guy M McKhann
- Department of Neurosurgery, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center , New York, New York , USA
-
- James J Riviello
- Division of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital , Houston, Texas , USA
-
- Roberta Rudà
- Division of Neuro-Oncology, Department of Neuroscience “Rita Levi Montalcini,” University of Turin , Italy
-
- David Schiff
- Department of Neurology, Division of Neuro-Oncology, University of Virginia School of Medicine , Charlottesville, Virginia , USA
-
- William O Tatum
- Department of Neurology, Mayo Clinic , Jacksonville, Florida , USA
-
- Jessica W Templer
- Department of Neurology, Northwestern University , Chicago, Illinois , USA
-
- Michael Weller
- Department of Neurology, Clinical Neuroscience Centre, University Hospital Zurich and University of Zurich , Zurich , Switzerland
-
- Patrick Y Wen
- Center for Neuro-Oncology, Dana-Farber Cancer Center, and Division of Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital , Boston, Massachusetts , USA
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Tumor-related epilepsy (TRE) is a frequent and major consequence of brain tumors. Management of TRE is required throughout the course of disease and a deep understanding of diagnosis and treatment is key to improving quality of life. Gross total resection is favored from both an oncologic and epilepsy perspective. Shared mechanisms of tumor growth and epilepsy exist, and emerging data will provide better targeted therapy options. Initial treatment with antiseizure medications (ASM) in conjunction with surgery and/or chemoradiotherapy is typical. The first choice of ASM is critical to optimize seizure control and tolerability considering the effects of the tumor itself. These agents carry a potential for drug–drug interactions and therefore knowledge of mechanisms of action and interactions is needed. A review of adverse effects is necessary to guide ASM adjustments and decision-making. This review highlights the essential aspects of diagnosis and treatment of TRE with ASMs, surgery, chemotherapy, and radiotherapy while indicating areas of uncertainty. Future studies should consider the use of a standardized method of seizure tracking and incorporating seizure outcomes as a primary endpoint of tumor treatment trials.</jats:p>
収録刊行物
-
- Neuro-Oncology
-
Neuro-Oncology 26 (1), 7-24, 2023-09-12
Oxford University Press (OUP)